Epoprostenol sodium for treatment of pulmonary arterial hypertension

The release of endogenous prostacyclin (PGI(2)) is depressed in patients with pulmonary arterial hypertension (PAH). PGI(2) replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epopro...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Vasc Health Risk Manag
Hoofdauteurs: Saito, Yukihiro, Nakamura, Kazufumi, Akagi, Satoshi, Sarashina, Toshihiro, Ejiri, Kentaro, Miura, Aya, Ogawa, Aiko, Matsubara, Hiromi, Ito, Hiroshi
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Dove Medical Press 2015
Onderwerpen:
Review
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4437604/
https://ncbi.nlm.nih.gov/pubmed/25999730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S50368
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items